Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. is offering 11,286,681 shares of common stock, with underwriters holding a 45‑day option to buy up to 1,693,002 additional shares. At an assumed price of $4.43, the company expects net proceeds of about $45.8 million (or $52.8 million with the option fully exercised), to fund working capital, manufacturing expansion, clinical trials and global marketing.
SS Innovations is a commercial-stage surgical robotics company selling its SSi Mantra system, with 168 systems installed across 10 countries and 7,885 procedures performed as of December 31, 2025. The business remains loss-making, with 2024 revenue of $20.65 million and a net loss of $19.15 million, and is seeking FDA 510(k) clearance and EU CE certification. Post‑offering, 205,643,381 shares will be outstanding, and the founder and CEO will still control over 55% of voting power, while risks include ongoing losses, financing needs, heavy regulation, data privacy obligations and possible U.S. tariffs.
SS Innovations International officer Milan Rao, the Global COO and CFO, has filed an initial ownership report showing beneficial ownership of 120,000 shares of common stock. These are restricted shares granted on January 16, 2026 under the company’s 2016 Incentive Stock Plan.
The restricted stock vests in 12 equal monthly installments of 10,000 shares, and each installment requires Rao’s continued service with the company and compliance with the other terms and conditions of the incentive plan.
SS Innovations International, Inc. director and COO - Americas Barry F. Cohen filed an amended Form 4 to correct previously reported ownership details. The amendment relates to a gift of 25,500 shares of common stock on 12/30/2025, reported with transaction code G at a price of $0.00 per share. After this correction, Cohen is shown as beneficially owning 7,838,088 shares of SS Innovations common stock in direct form.
The filing explains that it corrects a prior error where a 3,300 share gift had been inadvertently reported twice and also adjusts the total number of shares held following the reported transactions. This makes the insider ownership record more accurate but does not reflect a new purchase or sale for cash.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava, who is also a director and 10% owner, reported an indirect transaction in the company’s common stock. On 01/19/2026, a transaction coded “G” involved 10,000 shares of common stock at a price of $0.00 per share. After this transaction, 111,353,014 shares of common stock were reported as beneficially owned indirectly, held by Sushruta Pvt. Ltd., an entity in which Srivastava has a controlling interest and which is the holder of record.
SS Innovations International, Inc. insider entity uses shares to repay debt. Chairman and CEO Sudhir Srivastava, a director and 10% owner, reported two indirect transactions on January 17, 2026 involving common stock held by Sushruta Pvt. Ltd., an entity in which he has a controlling interest. Sushruta tendered 800,000 shares of SS Innovations common stock at $2.53 per share to satisfy principal and interest on a $2.0 million promissory note owed to a non‑affiliated third-party lender. On the same date, Sushruta tendered an additional 400,000 shares at $2.522 per share to satisfy principal and interest on a separate $1.0 million promissory note to a non‑affiliated lender. Following these dispositions, Srivastava reported 111,343,014 SS Innovations shares beneficially owned indirectly through Sushruta.
SS Innovations International, Inc. filed a current report to share that it has released preliminary, unaudited revenue and other selected operating metrics for the three and twelve months ended December 31, 2025. These figures were disclosed through a press release dated January 13, 2026, attached as Exhibit 99.1.
The company also provided an updated January 2026 Company Presentation as Exhibit 99.2, which it plans to use in communications with shareholders and the broader investment community. All of this information is being furnished under Items 2.02 and 7.01 of the report, meaning it is not treated as filed for liability purposes or automatically incorporated into other securities law filings.
SS Innovations International, Inc. reported a leadership change in its finance function. On January 2, 2026, former Chief Financial Officer Naveen Kumar Amar resigned for personal reasons. The board then appointed Milan Rao as both Global Chief Operating Officer and the new Chief Financial Officer on January 6, 2026, with his roles effective January 16, 2026.
Rao brings more than three decades of executive experience across technology, healthcare and global services, including senior roles at Markets & Markets, Smart Energy Water, Wipro and GE Healthcare. Under a one-year services agreement effective January 16, 2026, he will receive monthly base compensation of $41,667 and a stock grant of 120,000 shares of common stock under the company’s 2016 Incentive Stock Plan, vesting in equal monthly installments of 10,000 shares, subject to continued engagement and plan terms.
SS Innovations International, Inc. reported that it has completed development of five new 5-millimeter surgical instruments intended for clinical use. These instruments are designed for procedures across multiple specialties, including pediatric, cardiac, and head and neck surgery, as well as other operations involving smaller anatomical structures.
The update was disclosed in a current report and accompanied by a press release filed as an exhibit, highlighting expansion of the company’s instrument portfolio for delicate, small-structure surgery.
SS Innovations International, Inc. disclosed that its Chairman and CEO, Dr. Sudhir Srivastava, took part in an interview with Nasdaq’s Live From MarketSite on November 13, 2025, which was published on December 16, 2025. The video can be viewed on Nasdaq’s Live From MarketSite website and via the company’s investor overview page. The company emphasizes that this interview is being furnished, not filed, under Regulation FD and is not incorporated by reference into other SEC reports, and it includes standard cautionary language about forward-looking statements and related risks.
SS Innovations International, Inc. (SSII) reported an insider transaction by a director and officer serving as COO - Americas. On 10/08/2025, the insider reported a transaction in common stock coded "G," indicating a gift of 3,300 shares at a price of $0.00 per share. After this transaction, the insider beneficially owns 7,863,588 shares of SSII common stock in direct ownership. No derivative securities transactions were reported.